| pubmed-article:19384621 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C0029408 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C0009331 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C0008466 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C0017718 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19384621 | lifeskim:mentions | umls-concept:C0073578 | lld:lifeskim |
| pubmed-article:19384621 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19384621 | pubmed:dateCreated | 2009-4-22 | lld:pubmed |
| pubmed-article:19384621 | pubmed:abstractText | The purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary C-terminal cross-linking telopeptides of type II collagen (uCTX-II), and bone degradation, urinary C-terminal cross-linking telopeptides of type I collagen (uCTX-I), structural progression of osteoarthritis (OA) and potential therapeutic efficacy of type II collagen (COLLII) in combination with glucosamine and chondroitin sulfate (GC). | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19384621 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19384621 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:19384621 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19384621 | pubmed:issn | 1590-9921 | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:CoxD PDP | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:ScarpelliniMM | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:VignatiGG | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:MarrazzaM GMG | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:LuratiAA | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:TeleseFF | lld:pubmed |
| pubmed-article:19384621 | pubmed:author | pubmed-author:BellistriAA | lld:pubmed |
| pubmed-article:19384621 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19384621 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:19384621 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19384621 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19384621 | pubmed:pagination | 81-7 | lld:pubmed |
| pubmed-article:19384621 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:19384621 | pubmed:articleTitle | Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the "Magenta osteoarthritis study". | lld:pubmed |
| pubmed-article:19384621 | pubmed:affiliation | Rheumatology Unit, Magenta Hospital Italy, Via al Donatore di Sangue 50, 20013 Magenta, Milan, Italy. magda.scarpellini@ao-legnano.it | lld:pubmed |
| pubmed-article:19384621 | pubmed:publicationType | Journal Article | lld:pubmed |
